Ashim K Mitra
Overview
Explore the profile of Ashim K Mitra including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
231
Citations
4728
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alshamrani M, Sikder S, Coulibaly F, Mandal A, Pal D, Mitra A
AAPS PharmSciTech
. 2019 Jul;
20(7):254.
PMID: 31317354
The pathophysiological mechanisms for dry and wet age-related macular degeneration (AMD) involve oxidative stress and increased VEGF release and expression. An ideal drug candidate for both types of AMD is...
2.
Li G, Lee C, Agrahari V, Wang K, Navarro I, Sherwood J, et al.
Proc Natl Acad Sci U S A
. 2019 Jan;
116(5):1714-1722.
PMID: 30651311
Ocular corticosteroids are commonly used clinically. Unfortunately, their administration frequently leads to ocular hypertension, i.e., elevated intraocular pressure (IOP), which, in turn, can progress to a form of glaucoma known...
3.
Mandal A, Patel P, Pal D, Mitra A
AAPS PharmSciTech
. 2019 Jan;
20(2):66.
PMID: 30627825
Despite the great potential of peptides as therapeutics, there is an unmet challenge in sustaining delivery of sufficient amounts in their native forms. This manuscript describes a novel nanocarrier capable...
4.
Mandal A, Gote V, Pal D, Ogundele A, Mitra A
Pharm Res
. 2019 Jan;
36(2):36.
PMID: 30617777
Cequa®, a unique and first-in-class preservative free cyclosporine-A (CsA) nanomicellar topical formulation was recently approved by US FDA for treatment of dry eye disease or keratoconjuntivitis sicca (KCS). Being highly...
5.
Ngatuni M, Trinh H, Pal D, Mitra A
AAPS PharmSciTech
. 2018 Oct;
19(8):3871-3885.
PMID: 30306402
The objective of this study is to design, develop, and synthesize novel random triblock (RTB) copolymers for sustained delivery of macromolecules. RTB copolymers have not been utilized for the delivery...
6.
Wang K, Li G, Read A, Navarro I, Mitra A, Stamer W, et al.
Sci Rep
. 2018 Apr;
8(1):5848.
PMID: 29643342
It has been suggested that common mechanisms may underlie the pathogenesis of primary open-angle glaucoma (POAG) and steroid-induced glaucoma (SIG). The biomechanical properties (stiffness) of the trabecular meshwork (TM) have...
7.
Mandal A, Pal D, Agrahari V, Trinh H, Joseph M, Mitra A
Adv Drug Deliv Rev
. 2018 Jan;
126:67-95.
PMID: 29339145
The impact of proteins and peptides on the treatment of various conditions including ocular diseases over the past few decades has been advanced by substantial breakthroughs in structural biochemistry, genetic...
8.
Agrahari V, Patel S, Dhall N, Aulgur Z, Thukral S, Yang X, et al.
Drug Deliv Transl Res
. 2017 Nov;
8(2):422-435.
PMID: 29181835
The pentablock (PB) copolymers based composite nanosystems were designed to provide a long-term delivery of macromolecules to the back of the eye. A unique arrangement of each block (polyethylene glycol,...
9.
Agrahari V, Aulgur Z, Thukral S, Dhall N, Conley R, Mitra A
Recent Pat Inflamm Allergy Drug Discov
. 2017 Sep;
11(2):92-106.
PMID: 28901856
Background: Ocular inflammation and allergic eye diseases range from mild to severe may disturb visual function and affect` quality of life. Since these diseases require intensive therapies, the pathophysiology and...
10.
Agrahari V, Li G, Agrahari V, Navarro I, Perkumas K, Mandal A, et al.
Nanomedicine (Lond)
. 2017 Aug;
12(16):1911-1926.
PMID: 28756742
Aim: The aim of this study is to examine the elevation of MYOC in long-term treatment of human trabecular meshwork (HTM) cells using dexamethasone (DEX) encapsulated pentablock (PB) copolymer-based nanoparticles...